MarketCap
Facebook
X
Telegram
Midatech Pharma plc Income Statement 2025-2011 | MTP
Brief overview of profit and loss at Midatech Pharma plc
This overview is based on financial performance over the past five years. Midatech Pharma plc reported revenue of 1.9 million pounds sterling in 2018 and 381 thousand pounds sterling by 2023. The total change was −80.3%, with a CAGR of approximately −27.8%. Sales followed a declining trajectory over the five years.
The operating result measured by EBITDA moved from −11.8 million pounds sterling to −8 million pounds sterling, or +32.2%. Operating profitability strengthened faster than the scale of sales. At the operating-margin level, the figure shifted from −609.6% to −2103.4%. Cost pressure reduced operating profitability.
Across the five years, the net result shifted from −15 million pounds sterling to −7.1 million pounds sterling. Losses became smaller, but the business remains unprofitable.
Financial takeaway
The indicators point to a weaker financial profile. The financial profile benefits from improving net profitability. The main areas of concern are a softer top-line trend, a low EBITDA margin and a declining EBITDA margin. Investors should continue to monitor margins, costs, and earnings quality.
Annual Income Statement Midatech Pharma plc
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
- | 1.44 B | 91.6 M | 1.43 M | 79 M | 20.9 K | 23.6 K | 17.1 M | 27.1 M | 56.9 M | 66.2 M | - | - | - | - |
Shares |
54.9 B | 4.95 B | 316 M | 4.94 M | 80.5 M | 9.16 K | 9.16 K | 620 K | 521 K | 366 K | 285 K | - | - | - | - |
Historical Prices |
- | 0.29 | 0.29 | 0.29 | 0.981 | 2.28 | 2.58 | 27.5 | 52 | 143 | 228 | - | - | - | - |
Net Income |
-6.38 M | -5.73 M | -7.08 M | -7.66 M | -5.46 M | -22.2 M | -10.1 M | -15 M | -16.1 M | -20.2 M | -10.1 M | -7.38 M | -4.08 M | - | - |
Revenue |
- | - | 381 K | 699 K | 578 K | 343 K | 674 K | 1.94 M | 989 K | 6.92 M | 1.38 M | 157 K | 147 K | - | - |
Cost of Revenue |
- | - | - | - | - | - | - | - | 926 K | 667 K | 70 K | - | - | - | - |
Gross Profit |
- | - | - | - | - | - | - | - | - | -428 K | 1.3 M | - | 147 K | - | - |
Operating Income |
-8.64 M | -9.2 M | -8.01 M | -8.93 M | -7 M | -23 M | -11.3 M | -11.8 M | -13.3 M | -9.65 M | -12.9 M | - | - | - | - |
EBITDA |
-8.64 M | -9.2 M | -8.01 M | -8.93 M | -7 M | -23 M | -11.3 M | -11.8 M | -13.3 M | -14.8 M | -12.2 M | -7.56 M | -4.25 M | - | - |
Operating Expenses |
- | - | - | - | - | 4.78 M | 3.79 M | 2.6 M | 12.6 M | 18.7 M | 14.2 M | - | 4.65 M | - | - |
General and Administrative Expenses |
- | - | - | - | - | 4.95 M | 3.84 M | 4.39 M | 3.15 M | 9.22 M | 7.93 M | 4.4 M | 1.81 M | - | - |
All numbers in GBP currency
Quarterly Income Statement Midatech Pharma plc
| 2025-Q4 | 2025-Q2 | 2024-Q4 | 2024-Q2 | 2023-Q4 | 2023-Q2 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
54.9 B | 25.3 B | 4.95 B | 3.28 B | 316 M | 99.2 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Net Income |
-6.38 M | 3.81 M | -5.73 M | 3.31 M | -7.08 M | 3.57 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Revenue |
- | - | - | 298 K | 381 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Income |
-8.64 M | -4.02 M | -9.2 M | -4.22 M | -8.01 M | -4.24 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA |
-8.64 M | -4.02 M | -9.2 M | -4.22 M | -8.01 M | -4.24 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in GBP currency
The income statement is one of the three key financial reports of a company Midatech Pharma plc (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
Russia
USA
Canada
Germany
China
Israel
France
Britain
Belgium
